Prognosis in Patients with ST-Segment Elevation Myocardial Infarction Reperfused 
by PHDP: 1-Year MACEs Follow-Up

Jie Dou MS; Jie Gao MS; Hui-Hui Yang MS; Ruoling Guo MS; Chao Jiang MM; Jiang Zhou MD; Xiaomei Yu MS; Jingtao Guo MD; Jinlong Zhang MD; Donglei Luo MD

doi:10.1177/10760296241271394

Clinical and Applied Thrombosis/Hemostasis (Aug 2024)

Prognosis in Patients with ST-Segment Elevation Myocardial Infarction Reperfused by PHDP: 1-Year MACEs Follow-Up

Jie Dou MS,
Jie Gao MS,
Hui-Hui Yang MS,
Ruoling Guo MS,
Chao Jiang MM,
Jiang Zhou MD,
Xiaomei Yu MS,
Jingtao Guo MD,
Jinlong Zhang MD,
Donglei Luo MD

Affiliations

Jie Dou MS: School of Medicine, , Chengde 067000, Hebei, China
Jie Gao MS: School of Medicine, , Chengde 067000, Hebei, China
Hui-Hui Yang MS: School of Medicine, , Chengde 067000, Hebei, China
Ruoling Guo MS: School of Medicine, , Chengde 067000, Hebei, China
Chao Jiang MM: School of Medicine, , Chengde 067000, Hebei, China
Jiang Zhou MD: Department of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China
Xiaomei Yu MS: Department of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China
Jingtao Guo MD: Department of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China
Jinlong Zhang MD: Department of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China
Donglei Luo MD: Department of Cardiology, Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde 067000, Hebei, China

DOI: https://doi.org/10.1177/10760296241271394
Journal volume & issue: Vol. 30

Abstract

Read online

This study explored 1-year follow-up of Parmaco-invasive strategy with half-dose recombinant human prourokinase (PHDP) in patients with acute ST-segment elevation myocardial infarction (STEMI). The follow-up endpoints were major adverse cardiovascular events (MACEs) occurring within 30 days and 1 year, as well as postoperative bleeding events. The study ultimately included 150 subjects, with 75 in the primary percutaneous coronary intervention (PPCI) group and 75 in the PHDP group. This study found that the PHDP group had a shorter FMC-reperfusion time (42.00 min vs 96.00 min, P 0.05). The PHDP facilitates early treatment of infarct-related vessels, shortens FMC-reperfusion time, and does not increase the risk of MACEs.

Published in Clinical and Applied Thrombosis/Hemostasis

ISSN: 1076-0296 (Print); 1938-2723 (Online)
Publisher: SAGE Publishing
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://journals.sagepub.com/home/cat

About the journal